Platinum-Sensitive Fallopian Tube Carcinoma
3 clinical trials · Condition
◉ Watch Platinum-Sensitive Fallopian Tube Carcinoma
| Record | Firm | Date |
|---|---|---|
| Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors (NCT05002868) | Rhizen Pharmaceuticals SA | 2021-10-05 |
| Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer (NCT04034927) | National Cancer Institute (NCI) | 2019-12-04 |
| Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03691376) | Roswell Park Cancer Institute | 2019-03-08 |
Track Platinum-Sensitive Fallopian Tube Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.